SingleMetabolic / GLP-1Most referenced

Tirzepatide 10mg

Dual GIP and GLP-1 receptor agonist engineered to study synergistic incretin pathways in glycemic control and energy homeostasis.

Mechanism

Dual GLP-1/GIP receptor agonist; enhances glucose-dependent insulin release, suppresses glucagon, slows gastric emptying and reduces appetite.

Dosing

2.5–15 mg once weekly via gradual 4-week titration.

Reconstitution

Add 2.0 mL bacteriostatic water to one 10 mg vial → final concentration 5 mg/mL.

Storage

Lyophilized: freeze at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 2–4 weeks.

Mix & measure Tirzepatide 10mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Tirzepatide 10mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration5.00mg/mL

Draw volume0.500mL

On the syringe50.0units

Total doses in vial: 4.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Initiation (Weeks 1–4)	2.5 mg once weekly	50 units (0.50 mL)
Escalation Step 1 (Weeks 5–8)	5.0 mg once weekly	100 units (1.00 mL)

Reconstitution Steps

1
Remove the lyophilized 10 mg tirzepatide vial from -20 °C freezer storage and allow it to equilibrate to room temperature for approximately 15 minutes.
2
Disinfect the rubber stoppers of both the peptide vial and the bacteriostatic water vial using sterile alcohol prep pads.
3
Using an appropriate syringe, draw up precisely 2.0 mL of bacteriostatic water.
4
Insert the needle through the center of the peptide vial septum at a slight angle and dispense the diluent slowly down the inside glass wall to avoid foaming.
5
Gently swirl or roll the vial between your palms until the lyophilized cake is fully dissolved; do not shake vigorously.
6
Clearly label the vial with the reconstitution date, final concentration (5 mg/mL), and store upright refrigerated at 2–8 °C.

Supplies Needed

Peptide Vial

Lyophilized peptide target supplying 10 mg of active research compound per vial.

Insulin Syringes (U-100)

Low dead-space sterile syringes used for sampling, requiring roughly 1 syringe per weekly administration.

Bacteriostatic Water

Preserved diluent required to reconstitute the peptide cake, utilizing 2.0 mL per 10 mg vial.

Alcohol Swabs

70% isopropyl wipes for aseptic preparation of septa and injection sites, typically 2 swabs per session.

Why researchers study it

Weight regulation

Blood sugar control

Appetite & satiety

Cardiometabolic research

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Tirzepatide is a synthetic peptide engineered as a dual agonist of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Structurally derived from the native GIP sequence, it incorporates a C20 fatty diacid moiety that facilitates non-covalent albumin binding, extending its research half-life to approximately five days. By co-targeting two central incretin axes simultaneously, tirzepatide exhibits synergistic metabolic signaling compared to selective, single-receptor incretin mimetics. In experimental models, concurrent stimulation of GIP and GLP-1 receptors enhances insulin secretion in a glucose-dependent manner while suppressing inappropriate glucagon secretion. It delays gastrointestinal transit and modulates central hypothalamic signaling pathways responsible for energy intake, satiety, and lipid handling. Tirzepatide represents a prominent model peptide for investigating adiposity regulation, systemic insulin sensitivity, liver fat accumulation, and related cardiometabolic endpoints.

References

1.Jastreboff et al., N Engl J Med, 2022 — Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
2.Frías et al., N Engl J Med, 2021 — Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)
3.Galindo et al., Diabetes Ther, 2026 — Insights into the mechanism of action of tirzepatide